Pear

Pear announced plans to go public through a merger with a special purpose acquisition company in June, and the deal is set to close soon.

Around two million people receive coverage through Massachusetts' Medicaid program.

The study also found patients in the 24-week group had a 27% decrease in unique hospital encounters compared with the group who only received one prescription.

Researchers found patients who used reSET-O along with buprenorphine and counseling lowered their healthcare costs by $2,385 per person in the six months after they started using the app, compared with the six months before.

The company said the deal could help it with commercialization and expansion. 

The company made collaboration agreements with Empatica and etectRx, and a licensing deal with KeyWise. 

The study, backed by the digital therapeutics company, measured the change in clinical encounter frequency among opioid use disorder patients who were also prescribed buprenorphine.

The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.

One of the organization's main goals is to encourage Medicare and Medicaid reimbursement for prescription digital therapeutics. 

The PBM will be able to offer and administer benefit coverage for addiction-focused digital therapeutics.